D2R | DNA to RNA

Discover how lipid #nanoparticles are transforming gene therapy in a recent article co-authored by Pieter Cullis, from The University of British Columbia. "Delivery of genetic information to the interior of target cells in vivo has been a major challenge facing gene therapies. This barrier is now being overcome, owing in part to dramatic advances made by lipid-based systems that have led to lipid nanoparticles (#LNPs) that enable delivery of nucleic acid-based vaccines and therapeutics." 📚 Read "The 60-year evolution of lipid nanoparticles for nucleic acid delivery" in Nature Reviews Drug Discovery: https://lnkd.in/ek42xxRg 💻 Join us for a D2R webinar on Tuesday, July 16th, where Dr. Cullis will delve deeper into lipid nanoparticle technology: https://lnkd.in/eXBQ_rRr

📅 Join #D2R for a virtual webinar on Tuesday July 16, 2024, from 2-4 pm EDT where we will delve into the forefront of genomics and RNA research, and nanomedicine. 🔬 Register by Monday July 15 https://lnkd.in/eXBQ_rRr Presentations will include: 📣 Advancements in Genomic Research by Ioannis (Jiannis) Ragoussis, Head of Genome Sciences, McGill Genome Centre 📣 McGill's platforms in RNA Therapeutic Development and the new DePTAQ Services Network by Thomas Duchaine, Founding Director of McGill University's Centre for RNA Sciences. 📣 NanoCore, unlocking the power of Nanomedicine by Pieter Cullis, Professor, Biochemistry and Molecular Biology, The University of British Columbia Don’t miss this opportunity to engage with leaders in the field and gain insights that could help your research.

"#Genetics and other 'OMICS' sciences have the potential to transform healthcare for the better. Already, for a small but growing number of diseases and patients through personalized care, they offer a new chance at a healthy life. I find the prospect of some people being prevented from benefiting from these scientific developments because of concerns over genetic discrimination morally unacceptable." We spoke with Yann Joly, Professor in Human Genetics at McGill University, about his latest article on #geneticdiscrimination in Nature Genetics. In our conversation, Joly emphasized the importance of establishing a consensus definition across jurisdictions to address discrimination issues in genetic research. He also shares recommendations on how genetic discrimination should be taken into account in research, including within the context of #D2R. Read the interview here: https://lnkd.in/ewybUFz4

 📰 The June edition of the D2R Newsletter is out! This edition features open D2R Funding Programs and an interview about genetic discrimination. Lots of exciting announcements from the D2R community are also featured including the Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University being named a Host Institution for a global alliance dedicated to advancing human health through genomic data, recent RNA-related announcements in Quebec and more! 👀 Check out the newsletter: https://buff.ly/4cguXcn 🖋 Sign up for the D2R mailing list: https://buff.ly/4c4Foz7 L'infolettre est aussi disponible en français! 

Tomorrow is National Indigenous Peoples Day! Let's mark the occasion by celebrating the latest health research report on cultural safety that our Indigenous Professors have co-written. On June 6, Tahatikonhsontóntie' – the Quebec Network Environment in Indigenous Health Research (Qc-NEIHR), with the collaboration of Unité de Soutien SSA Québec, the Office of Joyce’s Principle and McGill's Department of Family Medicine with the support of the Indigenous Health Professions Program, unveiled the results of their report on cultural safety in the context of Indigenous health research. Cultural safety has emerged as a response to systemic racism that has been experienced by Indigenous Peoples in public services, and it has been expanded to research. Read more here: https://lnkd.in/g9gjMPB6 Alex McComber Treena Delormier Audrey Monette Deschenes Jennifer Petiquay-Dufresne Minnie Grey paul-yves weizineau Tahatikonhsontóntie' Quebec Network Environment for Indigenous Health Research McGill Faculty of Medicine and Health Sciences

🌟 Exciting news about McGill University's Victor Philip Dahdaleh Institute of Genomic Medicine🌟 We are thrilled to learn that the institute has been named of as one the Host Institutions of the Global Alliance for Genomics and Health (GA4GH), a not for profit alliance uniting the international community dedicated to advancing human health through #genomic data. The Victor Philip Dahdaleh Institute of Genomic Medicine is home to Centre of Genomics and Policy and Canadian Centre for Computational Genomics. The addition of this Host Institution will: ✔ Accelerate and expand the work of the GA4GH Regulatory & Ethics Work Stream, which develops guidance on the ethical, legal, and social issues in genomic research and international data sharing. ✔Tap into several technical communities, including The Pan-Canadian Genomic Library (led by Guillaume Bourque), which aims to facilitate responsible genomic data sharing across Canada, and EpiShare, an open science project that makes epigenomic datasets more accessible. Read more in the press release ⬇

Imagine a world where diseases are treated with precision. Three McGill University professors recently discussed the various ways in which scientific advances in genomics is transforming how we think about and treat diseases, like diabetes and cancer. 📽 Watch their discussion: https://lnkd.in/e52psjEK #GenomicRevolution #PrecisionMedicine

As a key player in CQDM's recently announced "RNA Therapy Development and Production Network", McGill University will play a crucial role by introducing a new therapeutic messenger RNA platform. This platform will cater to the requirements of ongoing activities and research being conducted by McGill's Centre for RNA Sciences, D2R | DNA to RNA research projects, as well as Network partner institutions and industries in the province. Messenger RNA modalities are key to the main therapeutic approaches emerging in precision medicine. The platform will offer services in bioproduction and the formulation of LNP nanoparticles on a pre-clinical level of various messenger RNA modalities, individually or collectively. Their quality control will be based on strict standardized criteria, as well as a functional base validation. Learn more about the Network's service platforms for advancing RNA therapies: https://lnkd.in/ec9bZHmX

🎉Félicitations à l'équipe du Centre des Sciences de l’ARN de McGill University pour la création du "Réseau de développement et de production de thérapies ARN". Mené par Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute, l’Université McGill et Université de Sherbrooke, ce Réseau s’inscrit parmi les cinq initiatives clés du projet mobilisateur sur les thérapies ARN annoncé le 30 avril dernier par le Gouvernement du Québec.

Nouvel appel à propositions d'AReNA! Plus de détails ci-dessous. ⬇ #RNA #ARN